Friday 6 November 2026 Export NORD’s income statement to Excel — free account

Nordicus Partners Corporation

Nordicus Partners Corporation’s revenue for fiscal 2025 (year ended March 2025) was $5,000.00, up 100.0% from fiscal 2024.

Revenue: −99.6%
EPS: −85.7%
Free cash flow: +62.2%

Quarter to June 2026, against a year earlier

3.40 0.33 −8.85%

Follow NORD

Alert me

Market cap: $63.2M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: 1.44
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 66.30%

Capital & Financial Ratios $m

Size

Market Cap 63.19

Revenue ttm 0.80

Net income ttm (5.15)

Free cash flow ttm (4.07)

Net debt Q (0.01)

Valuation

P/E 0.00

Forward P/E —

Price / sales 81.31

Forward P/S Powerpack

Price / FCF 0.00

Price / book 1.06

Financial health

Current ratio Q 0.18

Debt / equity Q 0.00

Interest coverage Q (431.37)

Growth

Revenue growth Q −99.58%

Operating income growth Q +1.48%

EPS, this year —

EPS, next year A —

Revenue, next year A —

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 92.04%

10-year low 10-year high

P/B against its own 10 years 22.83%

10-year low 10-year high

EV/Sales against its own 10 years 91.89%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	0	0	0	0
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	0	0	1	0

	2024	2025	2026	Q'26
Payables	0	1	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	0	1	1	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	(71.31%)	(87.02%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	279.14%	1,223.64%

EPS $

	Jun	Sep	Dec	Mar	Year
’26	(0.13)	—	—	—	—
’26	(0.07)	(0.08)	(0.07)	0.00	(0.22)
’25	(0.10)	(0.10)	(0.13)	0.00	(0.32)
’24	(0.05)	(0.10)	(0.07)	(0.10)	(0.30)
’23	(8.90)	(0.10)	(1.50)	(3.82)	(14.30)
’22	(0.83)	(2.59)	(8.51)	8.89	(3.00)
’21	(1.82)	(1.24)	(0.94)	(1.75)	(5.75)

Fiscal quarters ending in the months shown.

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	—	—	—	—	—
’25	—	0	0	0	0
’24	1	1	—	—	0
’18	1	1	1	1	3
’17	1	1	0	0	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Year
’26	—	—	—	—
’26	(2)	(1)	(1)	(4)
’25	0	0	0	(1)
’24	0	0	0	0
’23	0	0	0	0
’22	0	0	0	0
’21	0	0	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Year
’26	—	—	—	—
’26	(2)	(1)	(1)	(4)
’25	0	0	0	(1)
’24	0	0	0	0
’23	0	0	0	0
’22	0	0	0	0
’21	0	0	0	0

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	TTM Jun ’26	Trend	10 yrs	2027e	2028e	2029e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	2	3	—	—	—	—	—	0	0	—	1		(53.5%)	—	—	—	—
	Gross margin, %	62.65	72.62	—	—	—	—	—	100.00	100.00	—	70.18		+37.4 pt	Powerpack Nordicus Partners Corporation’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(1)	0	0	0	0	0	(8)	0	(3)	(4)	(5)		+25.9%
	EBT margin, %	(22.29)	(6.92)	0.00	0.00	0.00	0.00	0.00	(11,928.00)	(58,346.00)	0.00	0.00		+22.3 pt
	Net income	(1)	0	0	0	0	0	(8)	0	(3)	(4)	(5)		+25.9%
Per share, $
Per share, $	Revenue	53.12	67.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		n/m
	Earnings	(11.84)	(5.00)	7.77	115.00	(5.75)	(3.00)	(14.30)	(0.30)	(0.32)	(0.22)	(0.28)		(35.8%)
	Cash flow	(4.72)	2.51	(0.72)	112.51	(5.70)	(2.99)	(0.62)	(0.25)	(0.14)	(0.24)	(0.21)		(28.2%)
	Capex	0.00	(0.23)	2.05	44.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00		n/m
	Free cash flow	(4.72)	2.28	1.33	156.62	(5.70)	(2.99)	(0.62)	(0.25)	(0.14)	(0.24)	(0.21)		(28.2%)
	Book value	(13.98)	(11.70)	(3.40)	115.93	1.45	2.06	0.05	1.72	6.50	3.54	3.21		n/m
	Shares, m	0	0	0	0	0	0	1	1	9	18	18		+95.7%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	—	—	—	—	—	0.00	0.00	—	0.00		0.0
	P/S	0.41	0.26	—	—	—	—	—	2.16	54.55	—	81.31		14.3
	P/B	0.00	0.00	—	—	—	—	—	3.54	0.73	—	1.06		1.1
	EV/Sales	1.27	0.90	—	—	—	—	—	2.83	57.02	—	83.80		15.5
	EV/FCF	(14.31)	18.42	—	—	—	—	—	4.36	52.51	—	(16.50)		15.2
Cash, $m
Cash, $m	Operating cash flow	0	0	0	5	0	0	0	0	(1)	(4)	(4)		+40.5%
	Capex	—	0	0	2	—	—	—	—	—	0	0		+0.2%
	Free cash flow	0	0	0	7	0	0	0	0	(1)	(4)	(4)		+40.5%
Balance, $m
Balance, $m	Working capital	0	0	0	5	0	0	0	0	(1)	(1)	(1)		+4.7%
	Net debt	2	2	0	(6)	0	0	0	0	0	0	0		n/m
	Shareholders’ equity	(1)	(1)	0	5	0	0	0	2	60	64	62		n/m
Returns, %
Returns, %	ROA	(20.33)	(7.55)	11.32	126.94	(11.36)	(152.20)	(5,566.49)	(32.02)	(8.05)	(5.49)	(6.80)		+14.8 pt
	ROIC	(6.49)	8.30	0.00	0.00	0.00	0.00	(25,727.85)	(11.10)	(3.05)	(4.25)	(4.43)		+2.2 pt
	ROE	146.05	36.59	(102.93)	203.85	(11.69)	(207.74)	(7,625.74)	(32.97)	(9.41)	(6.45)	(8.06)		(152.5) pt
People
People	Employees	12	11	11	—	—	—	—	—	—	—	—		(4.3%)
	Revenue/emp, $m	0.19	0.27	0.00	—	—	—	—	0.00	0.00	—	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Mar 2025 · latest quarter Mar 2025 · fundamentals updated 2 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OKYO OKYO Pharma Limited Sponsored ADR	$73.5M	— (loss-making)	—	—	n/m	+37.39% (above 0%: growing)	0.00%	—	Compare
MNOV MediciNova, Inc.	$71.4M	— (loss-making)	— (loss-making)	+240.56% (above 0%: growing)	n/m	+16.75% (above 0%: growing)	69.33%	(554.36%)	Compare
NTRB Nutriband Inc.	$67.8M	— (loss-making)	4.6×	−29.72% (below 0%: shrinking)	n/m	+55.46% (above 0%: growing)	41.58%	(203.57%)	Compare
ACRV Acrivon Therapeutics, Inc.	$67.3M	— (loss-making)	—	—	n/m	+12.59% (above 0%: growing)	0.00%	0.00%	Compare
COYA Coya Therapeutics, Inc.	$65.9M	— (loss-making)	— (loss-making)	+48.96% (above 0%: growing)	n/m	−27.79% (below 0%: shrinking)	100.00%	(2,891.67%)	Compare
CNXU Conexeu Sciences Inc.	$65.4M	— (loss-making)	—	—	n/m	−1,084.33% (below 0%: shrinking)	—	0.00%	Compare
MAIA MAIA Biotechnology, Inc.	$64.2M	— (loss-making)	—	—	n/m	−63.23% (below 0%: shrinking)	—	0.00%	Compare
NORD Nordicus Partners Corporation	$63.2M	— (loss-making)	—	−99.58% (below 0%: shrinking)	n/m	+62.18% (above 0%: growing)	100.00%	0.00%
CRBP Corbus Pharmaceuticals Holdings, Inc.	$55.3M	— (loss-making)	— (loss-making)	−92.09% (below 0%: shrinking)	n/m	−78.52% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$66.6M	—	—	+9.62%	—	−7.60%	20.79%	0.00%

All 621 Biotechnology stocks →